CN104262302A - L-抗坏血酸-6-(e-2-癸烯酸)酯或其衍生物以及它们的应用 - Google Patents
L-抗坏血酸-6-(e-2-癸烯酸)酯或其衍生物以及它们的应用 Download PDFInfo
- Publication number
- CN104262302A CN104262302A CN201410442206.XA CN201410442206A CN104262302A CN 104262302 A CN104262302 A CN 104262302A CN 201410442206 A CN201410442206 A CN 201410442206A CN 104262302 A CN104262302 A CN 104262302A
- Authority
- CN
- China
- Prior art keywords
- ester
- acid
- medicine
- food
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002148 esters Chemical class 0.000 title claims abstract description 34
- 230000000694 effects Effects 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 33
- 235000013305 food Nutrition 0.000 claims abstract description 29
- 239000000126 substance Substances 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 241001465754 Metazoa Species 0.000 claims abstract description 7
- 239000012453 solvate Substances 0.000 claims abstract description 7
- 125000002252 acyl group Chemical group 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 25
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 23
- -1 animal-feed Substances 0.000 claims description 22
- 239000003900 neurotrophic factor Substances 0.000 claims description 21
- 102000008186 Collagen Human genes 0.000 claims description 16
- 108010035532 Collagen Proteins 0.000 claims description 16
- 230000006378 damage Effects 0.000 claims description 14
- 239000003845 household chemical Substances 0.000 claims description 13
- 230000001681 protective effect Effects 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 210000004185 liver Anatomy 0.000 claims description 10
- 239000000273 veterinary drug Substances 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 5
- 206010039966 Senile dementia Diseases 0.000 claims description 5
- 208000020339 Spinal injury Diseases 0.000 claims description 5
- 230000003327 cancerostatic effect Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010036049 Polycystic ovaries Diseases 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 208000031295 Animal disease Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 230000037182 bone density Effects 0.000 claims description 2
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 claims description 2
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims description 2
- 230000003779 hair growth Effects 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 230000002584 immunomodulator Effects 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 125000005644 linolenyl group Chemical group 0.000 claims description 2
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims description 2
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000019612 pigmentation Effects 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 35
- 238000002360 preparation method Methods 0.000 abstract description 7
- 235000013402 health food Nutrition 0.000 abstract description 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 239000000470 constituent Substances 0.000 description 10
- WXBXVVIUZANZAU-CMDGGOBGSA-N trans-2-decenoic acid Chemical group CCCCCCC\C=C\C(O)=O WXBXVVIUZANZAU-CMDGGOBGSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 9
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 9
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 208000024732 dysthymic disease Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 229940032362 superoxide dismutase Drugs 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010054089 Depressive symptom Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 210000001640 nerve ending Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 102100033857 Neurotrophin-4 Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229940109850 royal jelly Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- ZGDHFHMCRRTRAW-SNVBAGLBSA-N (3r)-3-methyldecanoic acid Chemical compound CCCCCCC[C@@H](C)CC(O)=O ZGDHFHMCRRTRAW-SNVBAGLBSA-N 0.000 description 1
- QHBZHVUGQROELI-SOFGYWHQSA-N (E)-10-hydroxydec-2-enoic acid Chemical compound OCCCCCCC\C=C\C(O)=O QHBZHVUGQROELI-SOFGYWHQSA-N 0.000 description 1
- WXBXVVIUZANZAU-UHFFFAOYSA-N 2-decenoic acid Chemical compound CCCCCCCC=CC(O)=O WXBXVVIUZANZAU-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 229910014033 C-OH Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 206010010214 Compression fracture Diseases 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 101710165567 Extracellular signal-regulated kinase 1 Proteins 0.000 description 1
- 101710165576 Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000016408 Podocarpus macrophyllus Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- QHBZHVUGQROELI-UHFFFAOYSA-N Royal Jelly acid Natural products OCCCCCCCC=CC(O)=O QHBZHVUGQROELI-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000162450 Taxus cuspidata Species 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- CMNWUCGLNTVCSI-UHFFFAOYSA-J [Na+].[Na+].[Na+].[Na+].[Cl-].[O-]P([O-])([O-])=O Chemical compound [Na+].[Na+].[Na+].[Na+].[Cl-].[O-]P([O-])([O-])=O CMNWUCGLNTVCSI-UHFFFAOYSA-J 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000037118 sensory ataxia Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000003977 synaptic function Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 1
- 239000012745 toughening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/62—Three oxygen atoms, e.g. ascorbic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一类新化合物及其应用,该类化合物为L-抗坏血酸-6-(E-2-癸烯酸)酯或其衍生物,或它们在食品、药学、兽药、动物饲料、日用化学品上可接受的盐或溶剂化物,涉及杂环化合物技术领域,所述L-抗坏血酸-6-(E-2-癸烯酸)酯或其衍生物的化学通式为 ,式中,R1 ~ 3=H或C2~20的脂肪族酰基,该类化合物可应用在药物、食品、保健食品、日用化学品、兽药或动物饲料等诸多领域,其制备方法简单,成本低廉,结构稳定,效果显著,具有很好的应用前景。
Description
技术领域
本发明涉及杂环化合物技术领域。
背景技术
L-抗坏血酸和王浆酸都是具有极强生物活性的物质,它们对于生物体具有良好的医疗和保健作用,经常被用于药物或保健食品中。
L-抗坏血酸的结构式为
I ,
L-抗坏血酸具有促进胶原合成、促进神经递质(5-羟色胺及去甲肾上腺素)合成、促进类固醇羟化、促进有机物或毒物羟化解毒、促进抗体形成、促进铁的吸收、促进四氢叶酸形成、维持巯基酶的活性等功能,此外,还具有解毒、预防癌症、清除自由基的作用。
E-2-癸烯酸是从蜂王浆中分离出的一种有机酸,其分子式为C10H18O2,化学名称为反式-2-癸烯酸,是蜂王浆的成分之一,E-2-癸烯酸的结构式为
II 。
神经细胞是具有信号转导功能的细胞,其损伤表现为严重的脑神经功能的丧失。在脑、脊髓的中枢神经中基本上无法期待轴突的再生,神经细胞存在损伤、变性的情况下,需要保护活化神经细胞。作为这样的生态防御机理,承担神经细胞的分化、生存维持、突触的功能亢进和损伤后的神经轴突的再生、修复的神经营养因子的作用是不可或缺的。
在神经营养因子中,神经生长因子、脑源性神经营养因子、神经营养蛋白-3和神经营养蛋白-4/5等构成了以神经生长因子为原型且具有50%以上的序列同源性的神经营养蛋白家族。分泌到细胞外的神经营养蛋白与神经细胞膜上的高亲和性受体结合时,在神经细胞内向三个方向转导信号,介由包括作为其中之一的MAP激酶(丝裂原激活蛋白(MAP)激酶/细胞外信号调节蛋白激酶1/2(ERK1/2))的活化(磷酸化)的MAP激酶信号转导通路的活化,转录因子的CREB(cAMP应答元件结合蛋白)被活化,大量的基因表达被控制。因此,若能够使介由MAP激酶信号转导通路的的信号转导活化,则能够临床应用于成因为神经细胞的变性或细胞死亡的神经障碍。另外,有关于脑源性神经营养因子(BDNF)与若干疾病的关联性的报道。
通过与脑源性神经营养因子(BDNF)的基因多态性有关的研究,有特定的多态性与帕金森病相关的报道(非专利文献1)、与阿尔兹海默氏病相关的报道(非专利文献2)、与抑郁症相关的报道(非专利文献3)、与两极型抑郁症相关的报道(非专利文献4)、与焦虑性相关的报道(非专利文献5)。有亨廷顿氏舞蹈病的基因突变小鼠的突触功能降低可以通过给与脑源性神经营养因子(BDNF)而恢复的报道(非专利文献6)、通过给与MAP激酶磷酸化抑制剂而引起的抑郁状态的报道(非专利文献7)。癸烯酸乙酯诱发细胞内的神经营养因子样信号,促进小鼠脑梗死功能的恢复(非专利文献8)。
在上述脑源性神经营养因子(BDNF)的例中也可知,神经营养因子对特定的神经疾病显示出治疗效果,具有使轴突发芽、延长的作用。但是,由于神经营养因子是高分子量的蛋白质,因此存在即使从末梢神经给药也无法通过血脑屏障而难以到达脑的问题,因此正在尝试探索具有利用低分子量化合物使神经细胞活化的神经营养因子样的作用的药物及促进神经营养因子的产生和分泌的药物。
专利文献1-4提出了含有具有规定通式的化合物的神经营养因子样的作用剂。专利文献5-7提出了含有具有规定通式的化合物的神经营养因子的产生和分泌促进剂,以及专利文献8提出了含有脂肪酸化合物、其酯或盐或它们的前药的神经再生促进剂。
专利文献9提出了含有具有规定通式的化合物、改善星形胶质细胞的GABA受体应答的降低并预防和治疗神经变性病等的药剂。
专利文献10提出了以碳原子数为6-10的中链脂肪酸、或碳原子数为6-10的中链脂肪酸的甲酯、乙酯、丙酯和正丁酯化合物作为有效成分的神经细胞分化诱导剂。
专利文献11记载了脂肪酸或脂肪酸酯具有神经营养因子样的作用。
专利文献12提出了L-抗坏血酸类和脂肪酸类组合物的胶原产生增强剂及其用途。
专利文献1描述了2-癸烯酸衍生物为烷基酯、酰胺、硫酯以及含有苯基、吡咯基、环烷基等共56共化合物。专利文献2-6中记载的神经营养因子样作用剂或神经营养因子的产生和分泌促进剂不以脂肪酸或脂肪酸的衍生物作为有效成分。在专利文献7中记载的神经再生促进剂中,公开了神经再生的药理活性的有效成分为(3R)-3-甲基癸酸。专利文献8中记载的预防和治疗神经变性病等的药剂以碳原子数为10(C10)以下的饱和脂肪酸、碳原子数为5(C5)的不饱和脂肪酸或饱和脂肪酸酯等作为有效成分。专利文献9中记载的神经细胞分化诱导剂以碳原子数为6-10的中链饱和脂肪酸、或碳原子数为6-10的中链饱和脂肪酸的酯作为有效成分。专利文献10以脂肪酸或脂肪酸酯作为有效成分。专利文献11中未具体公开癸烯酸衍生物,而且未记载神经营养因子样的作用。专利文献12提出了L-抗坏血酸葡糖苷和脂肪酸类混合得到的组合物的胶原产生增强剂及其用途。
现有技术文献
专利文献
1:CN103189350A
2:日本特开2000-7568
3:日本特开2003-113085
4:US8557864
5:日本特开2002-80467
6:日本特开2003-261545
7:国际公开第2003/084542
8:国际公开第2005/032535
9:日本特开平7-316092
10:日本特开平2007-217311
11:国际公开第2009/038110
12:CN1863526B、US20070129430。
非专利文献
1:Ann Neurol.2002 Jan;51(1):133-6
2:J Neural Transm.2005 May;112(5):703-11.EP 2004 Sep 14
3:Neuropsychopharmacology.2003 Feb;28(2):397-401.EP 2002 Aug 29
4:Br J Psychiary.2006 Oct;189:317-23
5:Psychopharmacology(Berl).2005 Jun;180(1):95-9.EP 2005 Jan 26
6:J Neurosci.2007Apr18;27(16):4424-34
7:BLOLPSYCHIATRY 2007;61:661-670
8:Yoshitaka Tanaka et. Int. J. Mol. Sci. 2012, 13, 4968-4981。
发明内容
本发明借鉴以往技术,目的在于提供一类新化合物L-抗坏血酸-6-(E-2-癸烯酸)酯(英文名称:L-ascorbyl(2E)-dec-2-enoate)或其衍生物,或它们在食品、药学、兽药、动物饲料、日用化学品上可接受的盐或溶剂化物,该类化合物的化学性质稳定,且具有营养神经、促进胶原蛋白产生、提高免疫力、抗氧化、防辐射等良好的生物活性,能够应用于药物、食品、保健食品、饮品、兽药、动物饲料、日用化学品等诸多领域。
为解决上述技术问题,本发明所采取的技术方案是:L-抗坏血酸-6-(E-2-癸烯酸)酯或其衍生物,或它们在食品、药学、兽药、动物饲料、日用化学品上可接受的盐或溶剂化物,该酯或其衍生物的化学通式为:
III ,
式中,R1~3=H(氢)或C2~20的脂肪族酰基(即含有2到20个碳的脂肪族酰基)。
作为优选,通式III中的R1~3为乙酰基、丙酰基、丁酰基、2-丁烯酰基、戊酰基、己酰基、辛酰基、壬酰基、癸酰基、癸烯酰基、油酰基、亚油酰基、亚麻酰基或棕榈酰基。
现将优选的部分化合物列于下表1。
本发明所称食品、药学、兽药、动物饲料、日用化学品上可接受的盐,可以是通式III化合物与磷酸、盐酸、硫酸或硝酸所形成的无机酸盐,也可以是与柠檬酸、酒石酸、乳酸或乙醇酸所形成的有机酸盐;所称的溶剂化物可以是水合物或醇合物。所述的盐及溶剂化物均可由现有技术简单地制得,且它们的生理效果与通式III化合物类似。
L-抗坏血酸-6-(E-2-癸烯酸)酯的合成是以L-抗坏血酸和E-2-癸烯酸为原料,通过脱水酯化生成L-抗坏血酸-6-(E-2-癸烯酸)酯,反应方程式如下:
,
脱水可以选用公知的方法,如采用H2SO4、SOCl2与叔胺、P2O5、DDC、草酰氯等脱水剂,反应溶剂可以选用公知的有机溶剂,如CH2Cl2、苯、甲苯、石油醚等,E-2-癸烯酸与L-抗坏血酸的摩尔比为1:1.1~1.5。反应结束后,采用公知的分离方法提纯精制(如提取、结晶、色谱、重结晶等),得到目标产物。还可以使用公知的方法对化合物1进行改造,生成酰基衍生物。
上述通式III化合物或其在食品、药学、日用化学品上可接受的盐或溶剂化物在药物、食品、保健食品、日用化学品、兽药或动物饲料中的应用。
作为优选,上述应用可以是指作为神经营养因子应用于治疗或预防老年痴呆、阿尔茨海默氏病、帕金森病、肌萎缩性侧索硬化、亨廷顿氏舞蹈病、进行性核上性麻痹、糖尿病神经病变、神经障碍或脊髓损伤的药物。
通式III表示的化合物具有神经营养因子样作用,因此可作为神经营养因子样作用剂,该神经营养因子样作用剂对神经障碍的预防或治疗有用。神经障碍是指起因于神经细胞的变性或细胞死亡使其功能受损的病态,包括神经变性病、精神病。神经变性病指痴呆、阿尔茨海默氏病、帕金森病、肌萎缩性侧索硬化(ALS)、杭延顿氏舞蹈病、进行性核上性麻痹(PSP)、糖尿病神经病变、视神经疾病的青光眼等。精神病指抑郁症(包括两极型的抑郁症)、焦虑障碍(神经症)、精神分裂症等。在用于抑郁症的情况下,以往已有的抑郁症治疗剂的三环类抗抑郁药、四环类抗抑郁药、选择性5-羟色胺再吸收抑制剂(SSRI)、5-羟色胺-去甲肾上腺再吸收抑制剂(SNRI)等到出现效果为止至少需要3-4周的时间,这期间必须定期服药,而本发明的神经营养因子样作用剂与已有的药物相比起效更快。
本发明还可作为脊髓损伤的治疗剂或修复剂。因交通事故、运动事故、老年人的压缩性骨折等而使脊髓受到物理性损害的脊髓损伤目前没有有效的治疗方法,而利用本发明的神经营养因子样作用效果,能够以安全性高的不饱和脂肪酸作为有效成分,期待通过向体内给药来治疗或修复脊髓损伤。
作为优选,上述应用可以是指应用于减轻抗癌剂所致副作用的药物。
通式III表示的化合物具有预防或减轻抗癌剂所致副作用的效果,特别是作为末梢神经障碍的减轻剂是有用的。此类抗癌剂可以举出紫杉醇、多西泰索扥紫杉烷系药剂,以及长春新碱、长春花碱、长春地辛、长春瑞滨等长春花生物碱系药剂。除此之外,作为通过利用神经细胞的伤害而引起轴突障碍从而引起末梢神经障碍的药剂,可以举出奥沙利铂、卡铂、顺氯氨铂、奈达铂等铂制剂。作为这些抗癌剂所引起的末梢神经障碍,可以举出刺痛、灼烧那样的痛感等疼痛,四肢末端的麻木、灼热感等感觉异常,对冷刺感的过敏等感觉过敏,感觉消失和感觉麻痹、感觉不舒适等感觉异常,以及感觉性共济失调、肌无力等症状。
作为优选,上述应用可以是指应用于具有减少肝脏化学损伤、延缓衰老或增加骨密度作用的食品、饮品、保健食品或药物。
作为优选,上述应用可以是指应用于具有增强动物抗病能力效果的免疫调节剂,或具有减少动物肝脏化学损伤效果的兽药。
作为优选,上述应用可以是指应用于具有增加胶原蛋白产生或减少辐射损伤效果的食品、饮品、保健食品或药物。
作为优选,上述应用可以是指应用于具有抑制黑色素形成、消除色素沉着、保护皮肤免受紫外线伤害、增加胶原蛋白产生或促进毛发生长作用的日用化学品。
作为优选,上述日用化学品包括但不限于洗发水、护发素、沐浴露、香皂、洗面奶、化妆品或护肤品。
本发明作为药物的给药形态没有特别限定,可以制成各种剂型,例如可以制备成注射剂或者胶囊剂、片剂、颗粒剂、散剂、丸剂、细颗粒剂等经口制剂,或直肠给药剂、油脂性栓剂、水性栓剂等各种其他制剂。
各种制剂能够通过添加药理上可接受的通常使用的赋形剂、结合剂、润滑剂、崩解剂、表面活性剂、助流剂等而制备。赋形剂包括乳糖、果糖、葡萄糖、玉米淀粉、山梨糖醇、结晶纤维素等等;粘合剂包括甲基纤维素、乙基纤维素、阿拉伯树胶、明胶、羟丙基纤维素、聚乙烯基吡咯烷酮等等;润滑剂包括滑石、硬脂酸镁、聚乙二醇、氢化植物油等等;崩解剂包括淀粉、藻酸钠、明胶、碳酸钙、柠檬酸钙、糊精、碳酸镁、合成硅酸镁等等;表面活性剂包括十二烷基硫酸钠、大豆软磷脂、蔗糖脂肪酸酯、聚山梨酸酯80等等;助流剂包括轻质无水硅酸、干燥氢氧化铝凝胶、合成硅酸铝、硅酸镁等等;添加剂包括糖浆、凡士林、甘油、乙醇、丙二醇、柠檬酸、氯化钠、磷酸钠等等。
关于含有本发明化合物药剂的给药量,可以根据患者的年龄、性别、症状、药剂类型等等因素设计,通常成人每天能够接受1-1000mg,优选为50-500mg。
采用上述技术方案所产生的有益效果在于:本发明L-抗坏血酸-6-(E-2-癸烯酸)酯或其衍生物保留了E-2-癸烯酸、L-抗坏血酸的原有功效,其在生理条件下分解出的E-2-癸烯酸和L-抗坏血酸均可作为有效成分起作用,并且还有相互促进的作用。与单纯的L-抗坏血酸相比,本发明增加了药理成分的稳定性和抗氧化性能;与单纯的L-抗坏血酸葡糖苷相比,本发明的抗氧化性能和促进成腺细胞增值活性更加优异。同时,L-抗坏血酸-6-(E-2-癸烯酸)酯或其衍生物还增加了药效成分的水中溶解度和生物利用效率,缩短了药物起效时间。此外,本发明化合物的合成方式简单,结构稳定,成本低廉,具有很高的生理活性,能够应用于药物、食品、保健食品、日用化学品、兽药或动物饲料等多种领域,具有广阔的应用范围和良好的应用前景。
附图说明
图1是实施例7中胶原产生试验的数据条形图。
具体实施方式
以下所列实施例仅仅是为了对本发明作出具体说明,不能视作对本发明保护范围的束缚和限制。
实施例1:L-抗坏血酸-6-(E-2-癸烯酸)酯的合成。
E-2-癸烯酸(17.25g,0.10mol)、L-抗坏血酸(22.91g,0.13mol)加入四口瓶中,加入溶剂二氯甲烷300ml,搅拌下加入三乙胺13.2g,滴加氯化亚砜15.4g。反应毕,将反应液倒入250ml水中,搅拌、静置,分出油层,用水100ml×3洗涤,脱除溶剂,用乙醇重结晶,得到白色晶体。
产物的理化参数为:
MW328.36;
MS(m/z+)328;
IR(v/cm)2450~3600(-OH)、1657(-CH=CH-共轭双键)、1700 (C=O)、1675(C=O,环内)。
1H NMR (CDCl3,ppm): 1.01(CH3,3H),1.20~1.75(br,10H,-CH2-×5),2.21(q,2H,-CH2-),3.73(O-C-H,1H),5.79(d,1H,=CH-),7.04(dt,1H,-CH=),8.31(=C-OH,1H)。
实施例2: 2、3、5-三乙酰基L-抗坏血酸-6-(E-2-癸烯酸)酯的合成。
L-抗坏血酸(2-癸烯酸)酯3.28g(0.01mol)加入四口瓶中,加入溶剂二氯甲烷100ml,搅拌及氮气保护下滴加乙酐3.8g(0.036 mol),反应毕,将反应液倒入250ml水中,搅拌、静置,分出油层,用300ml水分三次洗涤,每次100ml,脱除溶剂,用乙酸乙酯重结晶,得到产品3.75g,HPLC(高效液相色谱法)测得含量为98.5%,收率81.2%w。
2、3、5-三乙酰基L-抗坏血酸-6-(E-2-癸烯酸)酯纯品为白色晶体,其理化参数如下:
MW454.47;
MS(m/z+)454;
IR(v/cm)1656(-CH=CH-共轭双键)、1701 (C=O)、1674(C=O,环内);1745(O= C- CH3羰基)
1H NMR (CDCl3,ppm):1.20~1.75(br,10H,-CH2-×5),2.04(3H,CH3- C=O),2.21(q,2H,-CH2-),3.45(O-C-H,2H),3.62(t,2H,O-CH2-),3.73(O-C-H,1H),5.79(d,1H,=CH-),7.04(dt,1H,-CH=)。
实施例3:L-抗坏血酸-6-(E-2-癸烯酸)酯衍生物的合成。
如实施例2,衍生物的合成均可采用本技术领域的公知方法,如取代基为丙酰基时,丙酰化可以采用丙酸酐、丙酰卤+叔胺等与L-抗坏血酸-6-(E-2-癸烯酸)酯反应得到,产物的提纯则可以采用层析、重结晶等公知方法实现,化合物的确认也可通过公知方法测定。
实施例4: L-抗坏血酸-6-(E-2-癸烯酸)酯抗氧化试验。
选25~30g健康成年雌性小鼠(9月龄),用D-半乳糖600mg/kgBW颈背部皮下注射或腹腔注射造模,注射量为0.1mL/10g,每日1次,连续造模6周。随机分为1个模型对照组和3个受试样品剂量组(n=10~12),化合物溶解于0.1%DMSO(二甲基亚砜)中,并调整为10μg/ml、50μg/ml、250μg/ml的浓度,对照组只添加0.1%DMSO。3个受试样品剂量组经口给予受试样品,模型对照组给予同体积溶剂,在给受试样品的同时,模型对照组和各剂量组继续给予相同剂量D-半乳糖颈背部皮下或腹腔注射,30天取血,测MDA、SOD、GSH-PX,数据并用SPSS处理,结果见表2。
从表2结果分析,给药组与对照组MDA、SOD差异极显著(p<0.01),GPH-PX差异显著(p<0.05)。这提示本发明化合物出具有优异的抗氧化和延缓衰老的作用。
使用表1中其他化合物做同样试验,测得MDA与对照组MDA的比值如下表3所列。
由表3可以看出,本发明列举的化合物均具有较强的抗氧化功能。
实施例5: L-抗坏血酸-6-(E-2-癸烯酸)酯肝损伤保护作用试验。
成年雄性SD大鼠60只,适应性饲养3天后,随机分为4组(空白对照组、酒精模型组、低剂量组、高剂量组) ,每组15只;空白对照组每天给予蒸馏水灌胃,喂饲基础饲料;其余三组大鼠按12ml/ (kg.bw) (即12毫升每千克体重)剂量给予乙醇浓度为50%酒精溶液(以无水乙醇用纯净水稀释)灌胃,其中酒精模型组大鼠喂饲基础饲料。此外,低剂量组喂饲基础饲料+L-抗坏血酸-6-(E-2-癸烯酸)酯 (50mg/㎏饲料);高剂量组喂饲基础饲料+L-抗坏血酸-6-(E-2-癸烯酸)酯(100mg/㎏饲料) 。喂饲3周,试验期末,大鼠空腹12小时,取心脏血及肝脏,制备血清及10%肝匀浆,检测血清和肝组织谷丙转氨酶(ALT)、超氧化物歧化酶(SOD)、丙二醛(MDA) 等指标,并取肝组织作病理切片检查。数据统计分析见表4。
L-抗坏血酸-6-(E-2-癸烯酸)酯对酒精性肝损伤大鼠具有明显的保护作用,能提高机体SOD活性,降低MDA的含量,从而减轻自由基引发的肝脂质过氧化损伤,组织病理结果显示,高、低剂量组以及对照组均未发现组织病变。
表1所列其它化合物也具有类似作用。
实施例6:L-抗坏血酸-6-(E-2-癸烯酸)酯对应激负荷抑郁症状的抑制效果试验。
对于10周的SD雌性大鼠(n=10~12,n为雌性大鼠的个数)做如下处理:
(1)在15分钟的强迫游泳后,正常饲育2天;
(2)在倾斜的笼中饲育2天后,正常饲育1天;
(3)将笼的地垫润湿并饲育1天后,正常饲育1天;
(4)在以180转/分钟的速度旋转的笼中饲育1天后,正常饲育1天。
此外,重复两次(2)~(4),负荷应激共计三周,制作模型。期间,每天1次、持续3周,将本发明化合物溶解于DMSO的PBS(磷酸盐缓冲液)中,经口给药,通过悬尾试验进行抑郁症状的抑制效果评价。用手抓住距离雌性大鼠的尾前端1厘米的部位,保持在距离地10厘米的高度,观察6分钟,测定不动时间。显著性检验通过单因素SPSS多重检验。
上述悬尾试验的结果为,对照组(PBS经口给药)的不动时间为108.81±16.12秒,以600、1200μg/kgBW的用量给与本发明化合物的实验鼠,不动时间分别为86.56±15.63秒和62.15±13.25秒,可见本品对抑郁症状的抑制效果显著。
实施例7:L-抗坏血酸-6-(E-2-癸烯酸)酯的胶原产生作用试验。
将人成纤维细胞(NHDF)细胞按照细胞浓度达到2.5×104个/孔那样接种到含有添加了 10% (v/v) 胎牛血清与适量的青霉素改进的Eagle 培养基(称为“DMEM 培养基”)(pH7.1~7.4)的96孔微型板,在5%(v/v)CO2条件下、于37℃下培养24小时。然后,将培养上清用添加了规定浓度样品的DMEM培养基 200μL 进行交换,培养5天。然后,对上述微型板中的各孔的细胞的胶原产生量用胶原分析试剂盒进行定量。
就2-癸烯酸、2-癸烯酸+L-抗坏血酸-2-葡糖苷(AA2G)、L-抗坏血酸-(2-癸烯酸)酯的胶原产生增强作用进行研究。胶原分析,使用2-癸烯酸100μg/mL、2-癸烯酸100μg/mL+AA2G 50μM、100μg/mL L-抗坏血酸2-癸烯酸酯作为样品加入DMEM 培养基,研究由 2-癸烯酸 引起的胶原产生增强作用。结果如图1所示。
图1说明,本发明的化合物可以作为增强胶原蛋白产生的物质而应用于美容化妆品中,且其生产和使用成本均优于2-癸烯酸+AA2G。
实施例8:L-抗坏血酸-6-(2-癸烯酸)酯减少环磷酰胺副作用的试验。
环磷酰胺能够明显抑制溶血素的形成,而L-抗坏血酸-6-(2-癸烯酸)酯(连续给药15天,每天的给药量为10mg/kg)可拮抗环磷酰胺的抑制作用,但对正常小鼠的溶血素形成无明显影响(实验结果见表5)。
由此可见,本品对化疗药物如环磷酰胺的副作用具有明显的抑制效果。
表1所列其他部分化合物的试验结果见下表6,其中“给药”项目表示“环磷酰胺+表1所列化合物的编号”。
由表6可见,本发明的化合物对化疗药物如环磷酰胺的副作用具有明显的抑制效果。
实施例9:药物。
按照表7中所示比例,将各成分混合均匀,灌装成胶囊剂,每粒250mg。
按照表8中所示比例,将各成分混合均匀,压制成片剂,每片250mg,有效成分100mg。
将表9所示各成分按照规定混合比例均匀混合,利用常规方法压片,每片含300mg的本发明化合物。
以上药物可以作为脂肪肝、肝纤维化等肝脏疾病的治疗药物,作为胶原产生增强剂,作为保肝护肝药物,作为TGF-β产生增强剂,作为抗氧化药物,作为缓解抑郁症的药物,或是作为减轻患者的化疗毒副作用、减少放疗过程射线伤害的癌症化疗、放疗辅助药物,还可作为神经营养因子,用于治疗或辅助治疗退行性疾病或用于神经损伤的恢复。
实施例10:保健食品。
将表10中成分按照规定比例混合均匀,压制成片剂,每片300mg,有效成分含量90mg。
填充剂、粘结剂可以使用本技术领域公知的一种或几种物质。
实施例11:护肝保健食品。
按照表11中所示比例,将各成分混合均匀,灌装成胶囊剂,每粒250mg。本品能减少酒精、雾霾、重金属等有害物质对肝脏等器官造成的损伤。
饮酒后服用500mg,可以缓解饮酒后的身体不适等征状。
实施例12:食品。
将表12所示各成分按照规定混合比例均匀混合,通过常规方法于常温下减压干燥后,用粉碎机破碎,得到作为本发明粉末剂发挥功能的健康食品。本品适合用作包括人在内的动物的应激状况所造成的精神紧张、抑郁等。
本品作为具有柔和甜味和适度酸味,可以长期保存。本品由于可以直接或通过与适量的水等溶剂一起或分散于食物,可作为人以及宠物或家畜家禽等动物的口服摄取的组合物,对于鱼、兔、虾、蟹等养殖鱼贝类可以直接或混合在饵料等中使用。
实施例13:健康饮料。
将表13所示成分按规定比例在适当容器中均匀混合,使得到的混合物每质量份分散、溶解于去离子水49质量份中,按一份200g装入玻璃瓶中,灭菌后灌装得到健康饮料。
本品作为具有胶原产生增强作用的用于美容、护肝的健康饮料,方便使用。
实施例14:抗皱洗面奶。
将如表14所示的组分混合搅拌,加热到90℃,边搅拌边进行混合,持续30分钟,冷却至室温后,加入L-抗坏血酸(2-癸烯酸)酯,搅拌混合均匀,分装。
实施例15:皮肤外用护肤霜。
如表15所示,向成分1中添加成分2 ,于60℃下边加热搅拌边进行混合,冷却至室温后,加由规定混合量构成的成分3后,用氢氧化钾调到pH6.5后,用匀浆机乳化、分散,制造具有胶原产生增强作用的皮肤外用护肤霜。
本品通过来自于成纤维细胞的TGF-β产生诱导,增强皮肤中胶原产生,保存皮肤水嫩、赋予肌肤弹性和润滑,防止肌肤僵硬的效果、对肌肤的保湿作用效果也好,所以作为基础化妆品也有用。
总之,本发明合成了一类新的化合物,该类化合物为L-抗坏血酸-6-(10-羟基-2-癸烯酸)酯或其衍生物,此类化合物性质稳定,制备方法简单,成本低廉,并具有确实有效的生理活性,可以无副作用、安全地应用在制药、保健、日用化学、食品等诸多领域,拥有广阔的应用前景。
Claims (10)
1.L-抗坏血酸-6-(E-2-癸烯酸)酯或其衍生物,或它们在食品、药学、兽药、动物饲料、日用化学品上可接受的盐或溶剂化物,该酯或其衍生物的化学通式为:
,
式中,R1~3=H或C2~20的脂肪族酰基。
2.根据权利要求1所述的物质,其特征在于:R1~3为乙酰基、丙酰基、丁酰基、2-丁烯酰基、戊酰基、己酰基、辛酰基、壬酰基、癸酰基、癸烯酰基、油酰基、亚油酰基、亚麻酰基或棕榈酰基。
3.如权利要求1或2中所述的物质在药物、食品、饮品、保健食品、日用化学品、兽药或动物饲料中的应用。
4.根据权利要求3所述的应用,其特征在于:作为神经营养因子应用于治疗或预防老年痴呆、阿尔茨海默氏病、帕金森病、肌萎缩性侧索硬化、亨廷顿氏舞蹈病、进行性核上性麻痹、糖尿病神经病变、神经障碍或脊髓损伤的药物。
5.根据权利要求3所述的应用,其特征在于:应用于减轻抗癌剂所致副作用的药物。
6.根据权利要求3所述的应用,其特征在于:应用于具有减少肝脏化学损伤、延缓衰老或增加骨密度作用的食品、饮品、保健食品或药物。
7.根据权利要求3所述的应用,其特征在于:应用于具有增强动物抗病能力效果的免疫调节剂,或具有减少动物肝脏化学损伤效果的兽药。
8.根据权利要求3所述的应用,其特征在于:应用于具有增加胶原蛋白产生或减少辐射损伤效果的食品、饮品、保健食品或药物。
9.根据权利要求3所述的应用,其特征在于:应用于具有抑制黑色素形成、消除色素沉着、保护皮肤免受紫外线伤害、增加胶原蛋白产生或促进毛发生长作用的日用化学品。
10.根据权利要求9所述的应用,其特征在于:所述日用化学品包括洗发水、护发素、沐浴露、香皂、洗面奶、化妆品或护肤品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410442206.XA CN104262302B (zh) | 2014-09-02 | 2014-09-02 | L-抗坏血酸-6-(e-2-癸烯酸)酯或其衍生物以及它们的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410442206.XA CN104262302B (zh) | 2014-09-02 | 2014-09-02 | L-抗坏血酸-6-(e-2-癸烯酸)酯或其衍生物以及它们的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104262302A true CN104262302A (zh) | 2015-01-07 |
CN104262302B CN104262302B (zh) | 2016-05-11 |
Family
ID=52153916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410442206.XA Active CN104262302B (zh) | 2014-09-02 | 2014-09-02 | L-抗坏血酸-6-(e-2-癸烯酸)酯或其衍生物以及它们的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104262302B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109731005A (zh) * | 2019-02-19 | 2019-05-10 | 珠海壮元健康研究院有限公司 | 2-O-β-D-单糖基-L-抗坏血酸在防治神经退行性疾病药物中的应用 |
FR3092112A1 (fr) * | 2019-01-29 | 2020-07-31 | Arkema France | Huile de base lubrifiante synthetisee a partir d’esters de polyols et d’acides gras biosources |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1629303A (zh) * | 2004-08-24 | 2005-06-22 | 魏嘉士 | L-抗坏血酸不饱和脂肪酸酯酶催合成方法 |
CN1863526A (zh) * | 2003-10-07 | 2006-11-15 | 株式会社林原生物化学研究所 | 胶原产生增强剂及其制造方法和用途 |
EP1939192A1 (en) * | 2006-12-28 | 2008-07-02 | Neuropharma S.A. | Cyclopentanone derivatives, method of synthesis and uses thereof |
-
2014
- 2014-09-02 CN CN201410442206.XA patent/CN104262302B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1863526A (zh) * | 2003-10-07 | 2006-11-15 | 株式会社林原生物化学研究所 | 胶原产生增强剂及其制造方法和用途 |
CN1629303A (zh) * | 2004-08-24 | 2005-06-22 | 魏嘉士 | L-抗坏血酸不饱和脂肪酸酯酶催合成方法 |
EP1939192A1 (en) * | 2006-12-28 | 2008-07-02 | Neuropharma S.A. | Cyclopentanone derivatives, method of synthesis and uses thereof |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3092112A1 (fr) * | 2019-01-29 | 2020-07-31 | Arkema France | Huile de base lubrifiante synthetisee a partir d’esters de polyols et d’acides gras biosources |
WO2020157433A1 (fr) * | 2019-01-29 | 2020-08-06 | Arkema France | Huile de base lubrifiante synthetisee a partir d'esters de polyols et d'acides gras biosources |
CN113366095A (zh) * | 2019-01-29 | 2021-09-07 | 阿科玛法国公司 | 由多元醇酯和生物来源的脂肪酸合成的润滑基础油 |
JP2022518941A (ja) * | 2019-01-29 | 2022-03-17 | アルケマ フランス | ポリオールエステルおよび生物源脂肪酸から合成された潤滑基油 |
US11453833B2 (en) | 2019-01-29 | 2022-09-27 | Arkema France | Lubricating base oil synthesized from biosourced polyol and fatty acids esters |
JP7551627B2 (ja) | 2019-01-29 | 2024-09-17 | アルケマ フランス | 生物源のポリオールおよび脂肪酸エステルから合成された潤滑基油 |
CN109731005A (zh) * | 2019-02-19 | 2019-05-10 | 珠海壮元健康研究院有限公司 | 2-O-β-D-单糖基-L-抗坏血酸在防治神经退行性疾病药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104262302B (zh) | 2016-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102482249A (zh) | 用于治疗皮肤病症或疾病状态的tofa类似物 | |
CN110121337A (zh) | 药用化合物和营养补充剂 | |
JP2019001739A (ja) | サイクロデキストランおよびその誘導体の用途 | |
CN109476585A (zh) | 用于改善皮肤炎症或老化的新型的自噬激活诱导化合物 | |
AU2015100665A4 (en) | Composition containing eugenol as active ingredient for preventing or treating atopic dermatitis | |
CN104220041A (zh) | 含有牛蒡子苷元衍生物的抗老化剂 | |
WO2017111069A1 (ja) | 止痒剤 | |
CN104262302B (zh) | L-抗坏血酸-6-(e-2-癸烯酸)酯或其衍生物以及它们的应用 | |
RU2738648C2 (ru) | Применение соединения для лечения хронической тревоги или острой тревоги | |
CN104177318B (zh) | L-抗坏血酸-6-(10-羟基-2-癸烯酸)酯或其衍生物以及它们的应用 | |
KR102496282B1 (ko) | 사이토칼라신 d 또는 sag를 포함하는 항노화용 조성물 및 항노화 물질 스크리닝 방법 | |
CN115403546B (zh) | 愈创木烷类倍半萜衍生物及其制药用途 | |
JP5923375B2 (ja) | Cgrp応答性促進剤 | |
KR20140059958A (ko) | 양하 꽃잎의 추출물을 포함하는 비만 치료 및 개선용 조성물 | |
KR102037719B1 (ko) | 이오논을 유효성분으로 함유하는 항스트레스제, 항우울제 또는 항불안제 조성물 | |
JPH10120558A (ja) | 津液改善用皮膚外用剤 | |
KR101452061B1 (ko) | 아테미신산, 이의 유도체 및 이의 약학적으로 허용 가능한 염을 함유하는 피부 미백제 | |
KR101829587B1 (ko) | 4-하이드록시-2,3-디메틸-2-노넨-4-올라이드를 유효성분으로 포함하는 염증질환 또는 면역질환의 예방 및 치료용 약제학적 조성물 | |
WO2014148136A1 (ja) | 抗アレルギー活性化合物及びその用途 | |
JP2020189816A (ja) | ビタミンc誘導体組成物 | |
KR20170130278A (ko) | 디아세틸을 포함하는, 암 줄기세포 성장 억제용 조성물 | |
KR101777497B1 (ko) | 4-하이드록시-2,3-디메틸-2-노넨-4-올라이드 또는 3-하이드록시-4,7-메가스티그마디엔-9-원을 유효성분으로 포함하는 염증질환 또는 면역질환의 예방 및 치료용 약제학적 조성물 | |
WO2023119063A1 (en) | Placental composition | |
JP2014129268A (ja) | リパーゼ阻害剤 | |
KR20220008930A (ko) | 바닐라빈 추출물을 포함하는 피부 재생용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 050000 room 2106, building 1, science and technology center, No. 136, Huanghe Avenue, Shijiazhuang hi tech Zone, Shijiazhuang City, Hebei Province Patentee after: Hebei Fengtong Biotechnology Co., Ltd Address before: 050031 No. 266 Tianshan Avenue, hi tech Zone, Hebei, Shijiazhuang Patentee before: SHIJIAZHUANG KANGNUO BIOTECHNOLOGY CO., LTD. |
|
CP03 | Change of name, title or address |